BioSpace News Archive

Johnson & Johnson announced the appointment of several senior leaders to the Company’s Executive Committee.

Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA-Based Liquid Biopsy Platform for Early Cancer Detection.

Acquisition complements BD’s core portfolio - adding an innovative, broadly applicable surgical sealant to a suite of BD biosurgery products already relied upon in the operating room.

TYME Technologies, Inc today announced that its abstract, Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final phase II/III study results, has been accepted for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 20 – 22, 2022, in San Francisco, CA.

GRO Biosciences Inc. today announced the appointment of Bruce Beutel, PhD to its Board of Directors and its upcoming participation and activity during J.P. Morgan Health Care Week in January 2022.

Achilles Therapeutics plc today presented positive data at the ESMO Immuno-Oncology Congress 2021.

First Wave BioPharma, Inc., today announced the appointment of Brian Feagan, M.D., Professor of Medicine, Epidemiology and Biostatistics at Western University and Senior Scientific Director, Alimentiv, Inc., to First Wave BioPharma’s scientific advisory board.

Vivos Therapeutics, Inc today announced its official registration with Health Canada , a Minister of Health department responsible for helping Canadians maintain and improve their health through services and resources.

CinCor Pharma, Inc. (“CinCor”), announced today the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, in patients with uncontrolled hypertension and elevated plasma aldosterone levels, referred to as the High ALdOsterone (HALO) trial.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it has exceeded $1 million of revenue recognized from sales of its HTG Transcriptome Panel as of November 30, 2021.